已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Optimize Administration Protocol of Capecitabine Plus Docetaxel Combination in Metastatic Breast Cancer Patients

作者
Nicolas Frances,Christian Woloch,Hafedh Marouani,Cédric Mercier,Athanassios Iliadis
出处
期刊:Current Topics in Medicinal Chemistry [Bentham Science Publishers]
卷期号:12 (15): 1665-1668 被引量:1
标识
DOI:10.2174/156802612803531306
摘要

Combining several cytotoxics is the current mainstay for treating breast cancer patients. The combination between capecitabine and docetaxel was found to be more efficient than capecitabine or docetaxel when both were used as single agents. However, the administration protocol for this combination has been empirically chosen from single-agent trials. Based on already available population analysis, we propose here to optimize the administration protocol of this association so as to enhance efficacy while limiting treatment-related toxicity. Efficacy parameters evaluated from population analysis using a disturbed tumor growth model and safety characteristics from the available databases evidenced that: 1) Docetaxel is more efficient than capecitabine at the start of the treatment, but becomes less efficient next because of acquisition of resistance; 2) Over a long period of time, capecitabine is better tolerated than docetaxel. These characteristics allowed the following recommendations for an optimized modality of combination: 1) The treatment has to be started at the maximum tolerated dose for docetaxel; this dose should be individualized right from the start of the second cycle of treatment; 2) In parallel, capecitabine has to be started at a dose lower than its maximum tolerated dose. 3) When docetaxel becomes less efficient than capecitabine because of resistance, docetaxel dose has to be reduced but not discontinued. 4) If adverse events show during the treatment, it is recommended to reduce docetaxel, rather than capecitabine dosage. Combining modeling and statistical analysis of clinical data permit to optimize combination treatments. This procedure could be extended to others treatments involving combination of several cytotoxics.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云的应助被nap采纳,获得10
1秒前
1秒前
ChenH97完成签到 ,获得积分10
1秒前
2秒前
3秒前
wanci的应助被怀瑾握于丶采纳,获得10
3秒前
CodeCraft的应助被腼腆的立诚采纳,获得10
3秒前
5秒前
TreasureY发布了新的文献求助10
6秒前
活泼的夜云完成签到 ,获得积分10
7秒前
7秒前
neuroman发布了新的文献求助10
7秒前
8秒前
9秒前
10秒前
11秒前
李明之发布了新的文献求助10
12秒前
12秒前
chy发布了新的文献求助10
13秒前
sci2025opt完成签到 ,获得积分10
14秒前
禾电发布了新的文献求助10
17秒前
自私的猫发布了新的文献求助10
17秒前
18秒前
王化省发布了新的文献求助10
18秒前
lvli完成签到 ,获得积分10
18秒前
qianzhihe发布了新的文献求助10
18秒前
FF发布了新的文献求助10
22秒前
Akim的应助被腼腆的立诚采纳,获得10
24秒前
青柑普洱完成签到 ,获得积分10
26秒前
u562605完成签到,获得积分10
31秒前
almost发布了新的文献求助10
31秒前
Doraemon完成签到 ,获得积分10
33秒前
u362371完成签到,获得积分10
33秒前
u508882完成签到,获得积分10
35秒前
欢呼的雨琴完成签到 ,获得积分10
35秒前
TreasureY完成签到,获得积分20
35秒前
SciGPT的应助被FF采纳,获得10
37秒前
u360775完成签到,获得积分10
38秒前
u215055完成签到,获得积分10
38秒前
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184686
求助须知:如何正确求助?哪些是违规求助? 9573640
关于积分的说明 21832630
捐赠科研通 7782020
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558513
邀请新用户注册赠送积分活动 2481010